OR
Endocrinology - Diabetes
Diabetic kidney disease (DKD), a significant vascular complication associated with diabetes, is acknowledged as a major global health concern and the key reason for end-stage renal disease. Effective management of blood glucose concentration is essential for treating DKD, as the degree of glucose control directly influences the development of the disease. Using renin-angiotensin-aldosterone inhibitors to regulate blood pressure has demonstrated protective benefits against DKD. The GLP-1RA are among the newest treatment options for managing diabetes and slowing the progression of DKD. A recent clinical study evaluated the safety and efficacy of semaglutide in DKD. The findings of the study resulted in a decrease in eGFR levels in patients with DKD with moderate renal impairment .1 Discussed below is one such case:
0 Likes
0 Comments
Metabolic Minds Network is your ultimate destination for cutting-edge insights and compelling case studies in diabetology, tailored for physicians, endocrinologists, and diabetologists. Dive into the latest advancements and connect with peers to elevate your expertise and patient care. Join our dynamic network and stay at the forefront of diabetes management.
© 2024 Imedsource, All Rights Reserved
For unrestricted access to content and a seamless experience,